Mouse models for atherosclerosis and pharmaceutical modifiers
- PMID: 17541027
- DOI: 10.1161/ATVBAHA.107.142570
Mouse models for atherosclerosis and pharmaceutical modifiers
Abstract
Atherosclerosis is a multifactorial highly-complex disease with numerous etiologies that work synergistically to promote lesion development. The ability to develop preventive and ameliorative treatments will depend on animal models that mimic the human subject metabolically and pathophysiologically and will develop lesions comparable to those in humans. The mouse is the most useful, economic, and valid model for studying atherosclerosis and exploring effective therapeutic approaches. Among the most widely used mouse models for atherosclerosis are apolipoprotein E-deficient (ApoE-/-) and LDL receptor-deficient (LDLr-/-) mice. An up-and-coming model is the ApoE*3Leiden (E3L) transgenic mouse. Here, we review studies that have explored how and to what extent these mice respond to compounds directed at treatment of the risk factors hypercholesterolemia, hypertriglyceridemia, hypertension, and inflammation. An important outcome of this survey is that the different models used may differ markedly from one another in their response to a specific experimental manipulation. The choice of a model is therefore of critical importance and should take into account the risk factor to be studied and the working spectrum of the compounds tested.
Similar articles
-
The role of an experimental model of atherosclerosis: apoE-knockout mice in developing new drugs against atherogenesis.Curr Pharm Biotechnol. 2012 Oct;13(13):2435-9. Curr Pharm Biotechnol. 2012. PMID: 22280417 Review.
-
Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.Arterioscler Thromb Vasc Biol. 2017 Jul;37(7):1290-1300. doi: 10.1161/ATVBAHA.117.309630. Epub 2017 May 25. Arterioscler Thromb Vasc Biol. 2017. PMID: 28546220
-
Downregulations of CD36 and Calpain-1, Inflammation, and Atherosclerosis by Simvastatin in Apolipoprotein E Knockout Mice.J Vasc Res. 2017;54(3):123-130. doi: 10.1159/000464288. Epub 2017 Apr 28. J Vasc Res. 2017. PMID: 28448973
-
Anti-atherosclerotic effect of amlodipine, alone and in combination with atorvastatin, in APOE*3-Leiden/hCRP transgenic mice.J Cardiovasc Pharmacol. 2006 Jan;47(1):89-95. doi: 10.1097/01.fjc.0000195603.65858.27. J Cardiovasc Pharmacol. 2006. PMID: 16424791
-
Inflammation and atherosclerosis: novel insights into plaque formation and destabilization.Stroke. 2006 Jul;37(7):1923-32. doi: 10.1161/01.STR.0000226901.34927.10. Epub 2006 Jun 1. Stroke. 2006. PMID: 16741184 Review.
Cited by
-
Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets.Cytokine Growth Factor Rev. 2015 Dec;26(6):673-85. doi: 10.1016/j.cytogfr.2015.04.003. Epub 2015 May 12. Cytokine Growth Factor Rev. 2015. PMID: 26005197 Free PMC article. Review.
-
8-Hydroxy-2-deoxyguanosine prevents plaque formation and inhibits vascular smooth muscle cell activation through Rac1 inactivation.Free Radic Biol Med. 2012 Jul 1;53(1):109-21. doi: 10.1016/j.freeradbiomed.2012.03.023. Epub 2012 Apr 19. Free Radic Biol Med. 2012. PMID: 22580124 Free PMC article.
-
Foam Cells as Therapeutic Targets in Atherosclerosis with a Focus on the Regulatory Roles of Non-Coding RNAs.Int J Mol Sci. 2021 Mar 3;22(5):2529. doi: 10.3390/ijms22052529. Int J Mol Sci. 2021. PMID: 33802600 Free PMC article. Review.
-
Development of Antisense Drugs for Dyslipidemia.J Atheroscler Thromb. 2016 Sep 1;23(9):1011-25. doi: 10.5551/jat.RV16001. Epub 2016 Jul 27. J Atheroscler Thromb. 2016. PMID: 27466159 Free PMC article. Review.
-
Drugs that reverse disease transcriptomic signatures are more effective in a mouse model of dyslipidemia.Mol Syst Biol. 2015 Mar;11(3):791. doi: 10.15252/msb.20145486. Mol Syst Biol. 2015. PMID: 26148350 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous